UBS cuts rating on Regeneron stock amid Eylea uncertainty

13 hours ago · Investing.com -- UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 ...

$738
OFF

UBS Cuts Rating On Regeneron Stock Amid Eylea Uncertainty

1 week from now

yahoo.com

$738
OFF

UBS Downgrades Regeneron Pharmaceuticals To Neutral From …

1 week from now

18 hours ago · UBS Downgrades Regeneron Pharmaceuticals to Neutral From Buy, Cuts Price Target to $738 From $1,130 January 16, 2025 at 06:47 am EST Share This article is reserved …

marketscreener.com

$738
OFF

Regeneron Downgraded To Neutral From Buy At UBS

1 week from now

1 day ago · UBS downgraded Regeneron (REGN) to Neutral from Buy with a price target of $738, down from $1,130. The firm believes there is a disconnect between the market’s shorter-term …

businessinsider.com

$738.00
OFF

UBS Downgrades Regeneron Pharma (REGN) To Neutral

1 week from now

1 day ago · UBS analyst Trung Huynh downgraded Regeneron Pharma (NASDAQ: REGN) from Buy to Neutral with a price target of $738.00 (from $1,130.00).The analyst comments: "We …

streetinsider.com

85%
OFF

Regeneron Pharmaceuticals Analyst Ratings - Moomoo

1 week from now

DateUpside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/16/2025 5.85% UBS $1130 → $738 Downgrades Buy → Neutral 01/14/2025 …

moomoo.com

45%
OFF

Regeneron Pharmaceuticals Inc Equities - Advisors.ubs.com

1 week from now

Regeneron Pharmaceuticals Inc 1 August 2024 ab2 Regeneron Pharmaceuticals Inc UBS Research Highlights from 2Q24 call Eylea HD prefilled syringe launch now a high priority, anticipated in early 2025. The overall brand has maintained 45% share and that utilization in treatment naïve patients doubled sequentially. Increasing switchings from other

ubs.com

$1030.86
OFF

UBS Downgrades Regeneron Pharmaceuticals To Neutral From …

1 week from now

1 day ago · -- Regeneron Pharmaceuticals has an average rating of overweight and mean price target of $1,030.86, according to analysts polled by FactSet. ...

marketscreener.com

$738
OFF

Netflix Upgraded, AMD Downgraded: Wall Street's Top Analyst Calls

1 week from now

14 hours ago · UBS downgraded Regeneron to Neutral from Buy with a price target of $738, down from $1,130. UBS believes the stock's current valuation justifies its base business and pipeline …

yahoo.com

$738
OFF

UBS Downgrades Regeneron Pharmaceuticals To Neutral From …

1 week from now

UBS Downgrades Regeneron Pharmaceuticals to Neutral From Buy, Cuts Price Target to $738 From $1,130 MT Newswires Live 14分钟前 Regeneron Pharmaceuticals (REGN) has an …

laohu8.com

$1250
OFF

UBS Raises Price Target On Regeneron Pharmaceuticals To $1,250 …

1 week from now

Regeneron Pharmaceuticals Insider Sold Shares Worth $844,610, According to a Recent SEC Filing Nov. 05: MT UBS Cuts Price Target on Regeneron Pharmaceuticals to $1,130 From …

marketscreener.com

FAQs about UBS cuts rating on Regeneron stock amid Eylea uncertainty Coupon?

Why has UBS downgraded Regeneron Pharmaceuticals Inc (regn) to 'neutral'?

Investing.com -- UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 from $1130. The brokerage highlighted limited adoption of high-dose Eylea amid rising branded and biosimilar competition. ...

Is Regeneron a good fit for UBS?

While Regeneron’s pipeline holds promise in obesity and severe food allergies, UBS flagged long development timelines and the need for proof-of-concept data. Near-term upside from these programs remains limited. ...

What is the target price for Regeneron Pharmaceuticals?

This price target is based on 19 analysts offering 12 month price targets for Regeneron Pharmaceuticals in the last 3 months. The average price target is $697.15, with a high forecast of $844.00 and a low forecast of $536.00. The average price target represents a 19.71% upside from the last price of $582.37. ...

Is Regeneron a good stock to buy?

UBS noted that the stock’s valuation, trading at 15x earnings, reflects its innovation but sees investors pivoting to peers with stronger short-term growth. Regeneron shares are trading near pre-Eylea HD approval levels, which UBS considers fair value. ...

How many funds own Regeneron Pharmaceuticals?

There are 2,505 funds or institutions reporting positions in Regeneron Pharmaceuticals. This is an increase of 67 owner (s) or 2.75% in the last quarter. Average portfolio weight of all funds dedicated to REGN is -15.57%, an increase of 3,154.01%. Total shares owned by institutions increased in the last three months by 0.87% to 114,422K shares. ...

Are Regeneron shares a fair value?

Regeneron shares are trading near pre-Eylea HD approval levels, which UBS considers fair value. The volatile macro environment adds to downside risks, the note cautioned. ...